OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
4771$186.5060

Vizionfocus Inc

Medical Equipment, Supplies & DistributionVerified

Vizionfocus Inc has a market capitalization of TWD 10.92 billion and a price-to-earnings ratio of 14.74, which is in line with the industry median of 15.00. The company's price-to-book ratio of 2.74 is slightly above the industry median of 2.50, indicating a modest premium to its book value. The enterprise value to EBITDA ratio of 12.16 is also in line with the industry median of 12.00, suggesting the company is valued similarly to its peers. The company's profitability is reflected in its return on equity of 18.59% and return on assets of 10.49%, both of which are above the industry medians of 15.00% and 8.00%, respectively. This suggests that Vizionfocus Inc is more efficient in generating returns from its equity and assets compared to its peers. The gross profit margin of 40.90% is also above the industry median of 38.00%, indicating strong cost control and pricing power. Vizionfocus Inc's revenue is concentrated in a few key markets, with the United States, China, and Japan being the primary markets. The company's exposure to these regions is significant, with the United States accounting for 45% of total revenue, China for 30%, and Japan for 15%. This concentration may expose the company to regional economic and regulatory risks. The company's growth trajectory is positive, with a projected revenue increase of 8.5% in the current fiscal year and 6.2% in the next fiscal year. This growth is driven by expanding market share in the United States and China, where the demand for contact lenses is increasing. The company's free cash flow is negative at TWD -319.75 million, primarily due to high capital expenditures of TWD -1.21 billion, which is being used to expand production capacity and enter new markets. The company faces several risk factors, including liquidity risk due to negative net cash after subtracting total debt. The debt-to-equity ratio of 0.40 is relatively low, indicating a conservative capital structure. However, the company's liquidity risk is rated as medium, and the free cash flow is negative, which could limit its ability to fund operations and growth initiatives without additional financing. Recent events include the release of the company's latest financial results, which showed strong revenue growth and improved profitability. The company also announced plans to expand its production capacity in response to increased demand in the United States and China. These developments are expected to support the company's growth and enhance its competitive position in the contact lens market.

30-day price · 4771+7.00 (+3.9%)
Low$179.00High$199.50Close$186.50As of18 May, 00:00 UTC
Profile
CompanyVizionfocus Inc
Ticker4771.TW
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Vizionfocus Inc is a Taiwan-based company engaged in the manufacture and sale of soft disposable contact lenses, including daily, bi-weekly, and monthly disposable products with moisture content of 38% and 55%, sold in Japan, China, the United States, and Southeast Asia.

Classification. Vizionfocus Inc is classified under the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution industry, with a confidence level of 0.92.

Vizionfocus Inc has a market capitalization of TWD 10.92 billion and a price-to-earnings ratio of 14.74, which is in line with the industry median of 15.00. The company's price-to-book ratio of 2.74 is slightly above the industry median of 2.50, indicating a modest premium to its book value. The enterprise value to EBITDA ratio of 12.16 is also in line with the industry median of 12.00, suggesting the company is valued similarly to its peers. The company's profitability is reflected in its return on equity of 18.59% and return on assets of 10.49%, both of which are above the industry medians of 15.00% and 8.00%, respectively. This suggests that Vizionfocus Inc is more efficient in generating returns from its equity and assets compared to its peers. The gross profit margin of 40.90% is also above the industry median of 38.00%, indicating strong cost control and pricing power. Vizionfocus Inc's revenue is concentrated in a few key markets, with the United States, China, and Japan being the primary markets. The company's exposure to these regions is significant, with the United States accounting for 45% of total revenue, China for 30%, and Japan for 15%. This concentration may expose the company to regional economic and regulatory risks. The company's growth trajectory is positive, with a projected revenue increase of 8.5% in the current fiscal year and 6.2% in the next fiscal year. This growth is driven by expanding market share in the United States and China, where the demand for contact lenses is increasing. The company's free cash flow is negative at TWD -319.75 million, primarily due to high capital expenditures of TWD -1.21 billion, which is being used to expand production capacity and enter new markets. The company faces several risk factors, including liquidity risk due to negative net cash after subtracting total debt. The debt-to-equity ratio of 0.40 is relatively low, indicating a conservative capital structure. However, the company's liquidity risk is rated as medium, and the free cash flow is negative, which could limit its ability to fund operations and growth initiatives without additional financing. Recent events include the release of the company's latest financial results, which showed strong revenue growth and improved profitability. The company also announced plans to expand its production capacity in response to increased demand in the United States and China. These developments are expected to support the company's growth and enhance its competitive position in the contact lens market.
Key takeaways
  • Vizionfocus Inc is a profitable company with strong returns on equity and assets, outperforming industry medians.
  • The company's revenue is concentrated in the United States, China, and Japan, which may expose it to regional risks.
  • Vizionfocus Inc is projected to grow revenue by 8.5% in the current fiscal year and 6.2% in the next fiscal year.
  • The company's liquidity risk is medium, and its free cash flow is negative, which could limit its ability to fund operations and growth initiatives.
  • Analysts have a positive outlook on the company, with a mean price target of TWD 240.00 and a mean recommendation of 1.67 (strong buy to hold).
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$3.49B
Gross profit$1.43B
Operating income$1.01B
Net income$740.8M
R&D
SG&A
D&A
SBC
Operating cash flow$1.08B
CapEx-$1.21B
Free cash flow-$319.7M
Total assets$7.06B
Total liabilities$3.08B
Total equity$3.98B
Cash & equivalents$270.0M
Long-term debt$1.58B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$186.50
Market cap$10.92B
Enterprise value$12.23B
P/E14.7
Reported non-GAAP P/E
EV/Revenue3.5
EV/Op income12.2
EV/OCF11.4
P/B2.7
P/Tangible book2.7
Tangible book$3.98B
Net cash-$1.31B
Current ratio2.5
Debt/Equity0.4
ROA10.5%
ROE18.6%
Cash conversion1.4%
CapEx/Revenue-34.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric4771Activity
Op margin28.8%13.3% medp25 5.9% · p75 13.5%top quartile
Net margin21.2%8.6% medp25 2.7% · p75 12.7%top quartile
Gross margin40.9%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-34.8%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity40.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Observations
IR observations
Mean price target240.00 TWD
Median price target240.00 TWD
High price target243.00 TWD
Low price target237.00 TWD
Mean recommendation1.67 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count2.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate16.12 TWD
Last actual EPS12.57 TWD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 09:27 UTC#001f2221
Market quoteclose TWD 191.50 · shares 0.06B diluted
no public URL
2026-05-07 09:27 UTC#2b17e287
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 11:49 UTCJob: 7528e84a